Healthcare provider profile · identity verified

John Nicholas Walter, M.D.

Family Practice · KEENE, NH · NPI 1598779662

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	347	39
Furosemide	Furosemide	331	37
Gabapentin	Gabapentin	287	38
Potassium Chloride	Potassium Chloride	270	41
Atorvastatin Calcium	Atorvastatin Calcium	246	38
Eliquis	Apixaban	225	22
Trazodone Hcl	Trazodone Hcl	216	33
Metoprolol Succinate	Metoprolol Succinate	200	19
Amlodipine Besylate	Amlodipine Besylate	178	27
Sertraline Hcl	Sertraline Hcl	152	20
Losartan Potassium	Losartan Potassium	129	17
Warfarin Sodium	Warfarin Sodium	116	suppressed
Citalopram Hbr	Citalopram Hydrobromide	110	11
Metoprolol Tartrate	Metoprolol Tartrate	107	17
Prednisone	Prednisone	107	13
Escitalopram Oxalate	Escitalopram Oxalate	104	12
Tamsulosin Hcl	Tamsulosin Hcl	101	11
Mirtazapine	Mirtazapine	94	11
Venlafaxine Hcl Er	Venlafaxine Hcl	80	suppressed
Omeprazole	Omeprazole	75	11
Pantoprazole Sodium	Pantoprazole Sodium	74	12
Torsemide	Torsemide	74	suppressed
Duloxetine Hcl	Duloxetine Hcl	72	11
Risperidone	Risperidone	68	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	67	67
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	67	suppressed
Divalproex Sodium	Divalproex Sodium	64	suppressed
Allopurinol	Allopurinol	61	suppressed
Levetiracetam	Levetiracetam	56	suppressed
Lisinopril	Lisinopril	56	13
Diclofenac Sodium	Diclofenac Sodium	55	suppressed
Lorazepam	Lorazepam	55	26
Oxycodone Hcl	Oxycodone Hcl	54	21
Fentanyl	Fentanyl	52	11
Hydrochlorothiazide	Hydrochlorothiazide	52	suppressed
Cephalexin	Cephalexin	49	12
Famotidine	Famotidine	49	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	49	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	49	suppressed
Digoxin	Digoxin	48	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	47	suppressed
Metformin Hcl	Metformin Hcl	47	suppressed
Carvedilol	Carvedilol	45	suppressed
Humalog	Insulin Lispro	44	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	44	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	41	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	40	suppressed
Spironolactone	Spironolactone	39	suppressed
Metformin Hcl Er	Metformin Hcl	38	suppressed
Morphine Sulfate	Morphine Sulfate	37	27
Tramadol Hcl	Tramadol Hcl	36	suppressed
Pravastatin Sodium	Pravastatin Sodium	34	suppressed
Latanoprost	Latanoprost	33	suppressed
Albuterol Sulfate	Albuterol Sulfate	32	11
Hydrocortisone	Hydrocortisone	32	15
Ketoconazole	Ketoconazole	32	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	31	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	30	suppressed
Glipizide	Glipizide	30	suppressed
Simvastatin	Simvastatin	29	suppressed
Baclofen	Baclofen	28	suppressed
Donepezil Hcl	Donepezil Hcl	27	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Nuplazid	Pimavanserin Tartrate	25	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	16
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	24	suppressed
Finasteride	Finasteride	24	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	23	17
Insulin Lispro	Insulin Lispro	23	suppressed
Enulose	Lactulose	22	suppressed
Humulin N Kwikpen	Insulin Nph Human Isophane	21	suppressed
Methimazole	Methimazole	20	suppressed
Paroxetine Hcl	Paroxetine Hcl	20	suppressed
Phenobarbital	Phenobarbital	20	suppressed
Amiodarone Hcl	Amiodarone Hcl	19	suppressed
Amoxicillin	Amoxicillin	19	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	18	suppressed
Aripiprazole	Aripiprazole	18	suppressed
Novolin N Flexpen	Insulin Nph Human Isophane	18	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	18	suppressed
Insulin Aspart Flexpen	Insulin Aspart	17	suppressed
Clopidogrel	Clopidogrel Bisulfate	16	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	16	suppressed
Jardiance	Empagliflozin	16	suppressed
Metolazone	Metolazone	16	suppressed
Incruse Ellipta	Umeclidinium Bromide	15	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	15	suppressed
Klor-Con 10	Potassium Chloride	15	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Zonisamide	Zonisamide	15	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	14	suppressed
Bupropion Xl	Bupropion Hcl	13	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	13	suppressed
Cholestyramine	Cholestyramine (With Sugar)	13	suppressed
Clonazepam	Clonazepam	13	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	13	suppressed
Memantine Hcl	Memantine Hcl	13	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	13	suppressed
Temazepam	Temazepam	13	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	12	suppressed
Estradiol	Estradiol	12	suppressed
Fluticasone Propionate	Fluticasone Propionate	12	suppressed
Montelukast Sodium	Montelukast Sodium	12	suppressed
Rybelsus	Semaglutide	12	suppressed
Valacyclovir	Valacyclovir Hcl	12	suppressed
Betamethasone Dipropionate	Betamethasone Dipropionate	11	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Sotalol	Sotalol Hcl	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error